Compare Ares Capital Corporation (ARCC) vs Baxter International Inc (BAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ares Capital Corporation vs Baxter International Inc — how do they compare? Ares Capital Corporation trades at $20 (market cap $14.34B), while Baxter International Inc trades at $27.56 (market cap $14.27B). The key difference: Ares Capital Corporation and Baxter International Inc are close in size by market cap, and Ares Capital Corporation pays the higher dividend (9.61%). Which is the better fit depends on your goals.
| ARCC | BAX | |
|---|---|---|
Market Cap | $14.34B | $14.27B |
Sector | Financials | Health |
52-Week High | $22.68 | $28.35 |
52-Week Low | $17.45 | $15.80 |
Dividend Yield | 9.61% | 0.14% |
Enterprise Value | — | $21.79B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARCC trades at $19.98, down 0.15% on the day, with a P/E of 14.9 and P/B of 1.03. Recent quarterly earnings have consistently missed expectations, with Q2 2026 EPS of $0.47 falling short of the $0.4731 estimate. Technical indicators show a bullish moving average signal but bearish oscillators, with RSI at 78.37 suggesting overbought conditions. The company maintains a strong dividend yield of approximately 9.6% with consistent $0.48 quarterly payments.
While ARCC offers attractive income with its high dividend yield and strong analyst support (24 buy ratings), investors face risks from declining revenue trends and compressed earnings. The stock trades near consensus price targets, limiting near-term upside potential. Credit quality concerns in the private lending sector and potential interest rate sensitivity present additional headwinds for this business development company.
Baxter International Inc. (BAX) trades at $27.78, up 0.83% today, with a bullish technical outlook supported by moving averages. Recent Q2 2026 earnings beat estimates with EPS of $0.56 versus $0.37 expected, and revenue guidance was raised, signaling operational improvement. However, the company posted a net loss of -$957 million in 2025, with negative profit margins and high P/E of 87.85, reflecting valuation concerns amid turnaround efforts.
The stock shows potential from earnings momentum and cost initiatives, but high debt and inconsistent profitability pose risks. Analyst consensus is mixed with a $25.43 price target below current levels, suggesting cautious optimism. Investors should weigh recent beats against structural challenges in the medtech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ares Capital Corporation
Ares Capital Corp is a United States-based closed-ended specialty finance company. Its investment objective is to generate both current income and capital appreciation through debt and equity investments. The company focuses on investing primarily in U.S. middle-market companies with investment opportunities as well as in larger companies. Its portfolio comprises of first lien senior secured loans, second lien senior secured loans, and mezzanine debt (subordinated unsecured loan), which may include equity components that are diversified by industry and sector. The company may invest in preferred and common equity investments to a lesser proportion. Its revenue mainly consists of interest and dividend income received from the investment made.
Read more on ARCC →About Baxter International Inc
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, and administrative sets.
Read more on BAX →
